Llwytho...
Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
A germline pathogenic variant in BRCA2 was secondarily found through genomic sequencing of uterine serous carcinoma. Clinical response to olaparib was observed in recurrent uterine serous carcinoma with a germline BRCA2 mutation. Here, we report, for the first time, a long-term clinical response to...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Gynecol Oncol Rep |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Elsevier
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7152717/ https://ncbi.nlm.nih.gov/pubmed/32300630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2020.100563 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|